RenovoRx PK substudy shows >50% reduction in systemic drug exposure with RenovoTAMP

RenovoRx, Inc.

In 13 LAPC patients, intra-arterial gemcitabine via RenovoTAMP reduced systemic drug exposure by >50% vs IV.
Data presented at ASCO GI Symposium January 19-21, 2023, along with three additional abstracts.
TIGeR-PaC trial: 47 of 114 target patients randomized; 25 deaths reported to date.
Additional abstracts cover mesenteric venous thrombosis prevalence and SBRT vs IMRT tolerability.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.